Grand Pharmaceutical Group Ltd

Chart & Performance

D1W1MN

No data to show

P/E

11.79

P/S

2.11

EPS

0.54

Div Yield, %

4.11%

Shrs. gr., 5y

4.68%

Rev. gr., 5y

12.06%

Revenues

10.53b

+10.12%

Net income

1.88b

-9.59%

CFO

2.42b

+26.49%

Dividend

Jun 06, 20240.26 HKD/sh

Profile

Grand Pharmaceutical Group Limited, an investment holding company, engages in the research and development, manufacture, and sale of pharmaceutical preparations and medical devices, biotechnology and healthcare products, and pharmaceutical raw materials. The company offers pharmaceutical preparations, including cerebro-cardiovascular emergency medicines; respiratory, ophthalmic, anti-infection, and ENT medicines; oncology medicines; and rare disease medicines. It also provides medical devices, such as vascular interventional medical devices comprising paclitaxel releasing coronary balloon dilatation catheters and paclitaxel releasing hemodialysis shunt balloon dilatation catheters; and ophthalmology related devices. In addition, the company offers biotechnology and health products, such as Taurine, amino acid products, steroid products, and bio-pesticides and agricultural antibiotics; and specialized pharmaceutical raw materials and other products, including metronidazole, chloramphenicol, epinephrine, dimethyl sulfate, nitromethane, etc. Further, the company offers agrochemicals, fine chemicals, and chemical medicines; ophthalmic gel and eye drops; steroid hormones active pharmaceutical ingredients and related intermediates; bio-pesticides and additives; disposal surgical products; and Chinese medicine and health food products, as well as engages in the treatment of sewage. Grand Pharmaceutical Group Limited has a strategic cooperation agreement with the Eye Hospital of Wenzhou Medical University in the field of ophthalmic drug research and development. It operates in the People's Republic of China, the rest of Asia, the United States, Europe, and internationally. The company was formerly known as China Grand Pharmaceutical and Healthcare Holdings Limited and changed its name to Grand Pharmaceutical Group Limited in November 2021. Grand Pharmaceutical Group Limited was incorporated in 1995 and is based in Central, Hong Kong.

URL

http://chinagrandpharm.com/

IPO date

Dec 19, 1995

Employees

10,124

Domiciled in

Incorporated in

Valuation

Order:

Title HKD in thousands, except ratios and share amounts	FY	FY	FY	FY	FY	FY	FY	FY	FY
Title HKD in thousands, except ratios and share amounts	2023‑12	2022‑12	2021‑12	2020‑12	2019‑12	2018‑12	2017‑12	2016‑12	2015‑12
Income
Revenues	10,529,590 10.12%	9,562,285 11.22%
Cost of revenue	8,379,514	7,319,281
Unusual Expense (Income)
NOPBT	2,150,076	2,243,004
NOPBT Margin	20.42%	23.46%
Operating Taxes	448,755	418,642
Tax Rate	20.87%	18.66%
NOPAT	1,701,321	1,824,362
Net income	1,879,998 -9.59%	2,079,419 -13.45%
Dividends	(496,940)	(390,450)
Dividend yield
Proceeds from repurchase of equity	(81,014)	(54,843)
BB yield
Debt
Debt current	2,352,597	3,252,911
Long-term debt	1,147,867	1,222,371
Deferred revenue	240,105	265,281
Other long-term liabilities		60,083
Net debt	(7,195,754)	(6,455,264)
Cash flow
Cash from operating activities	2,424,895	1,917,084
CAPEX	(487,727)	(1,671,297)
Cash from investing activities	(515,747)	(2,577,871)
Cash from financing activities	(1,889,399)	464,493
FCF	1,363,777	944,084
Balance
Cash	2,474,298	2,483,953
Long term investments	8,221,920	8,446,593
Excess cash	10,169,738	10,452,432
Stockholders' equity	8,894,697	7,751,827
Invested Capital	10,020,163	10,827,658
ROIC	16.32%	17.42%
ROCE	11.24%	11.93%
EV
Common stock shares outstanding	3,507,754	3,542,258
Price
Market cap
EV
EBITDA	2,542,286	2,637,916
EV/EBITDA
Interest	205,145	137,493
Interest/NOPBT	9.54%	6.13%